<DOC>
	<DOCNO>NCT01902472</DOCNO>
	<brief_summary>This study evaluate HIV-1 RNA presence absence resistance baseline follow seroconversion , assess frequency HIV-1 screening screen method ( ) use evaluation seroconverters , collect information regard whether seroconverter experience sign symptom acute HIV-1 infection prior time seroconversion .</brief_summary>
	<brief_title>A Prospective , Observational Study Individuals Who Seroconvert While Taking Truvada® Pre-Exposure Prophylaxis ( PrEP )</brief_title>
	<detailed_description />
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Participant FTC/TDF PrEP demonstration project FTC/TDF PrEP clinical study HIV1 negative adult ( sex/gender , include transgender ) ≥ 18 year age time enrollment demonstration project clinical study . Evidence seroconversion receive FTC/TDF PrEP This observational nested study monitor report seroconversions without intervention/exclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Truvada</keyword>
	<keyword>FTC/TDF</keyword>
	<keyword>Pre-exposure prophylaxy</keyword>
	<keyword>PrEP</keyword>
	<keyword>Resistance</keyword>
</DOC>